Stocks
Amgen Inc.AMGN
NASDAQHealthcareBiotechnology$366.21-0.43%
A leading biotechnology company focused on developing and manufacturing biologic therapies for oncology, cardiovascular disease, inflammation, and rare disorders. Its portfolio includes blockbuster drugs such as Enbrel, Prolia, and Otezla, alongside a growing pipeline of biosimilars and novel biologics. Investors closely monitor product sales concentration, patent expirations, clinical trial outcomes, and capital allocation as key drivers of revenue growth and margin stability.
Market Cap: $197.4B52W Range: $261.43 – $391.29
Congressional Interest in Amgen Inc. (AMGN)
21 members of Congress have disclosed 50 trades in Amgen Inc. (AMGN), a Healthcare company. The buy/sell breakdown shows 36 purchases versus 14 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
21
Buys
36
Sells
14
Who in Congress Is Trading AMGN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-03-17 | Tom Price | sell | $1K – $15K |
| 2016-03-08 | MICHAEL T. MCCAUL | sell | $1K – $15K |